• PCV72 ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA ACCORDING TO THE AGE OF ONSET- USING NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PIH41 PRESCRIPTION PATTERNS AND EXPENDITURE OF LONG-TERM BENZODIAZEPINE TREATMENT IN ELDERLY OUTPATIENTS IN TAIWAN

    Oct 1, 2009, 00:00

  • PDB50 THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN WORKING ADULTS

    Oct 1, 2009, 00:00

  • PCN138 INFORMATION NEEDS- A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT

    Oct 1, 2009, 00:00

  • PSS24 COST EFFECTIVENESS ANALYSIS OF TAFLUPROST COMPARED WITH LATANOPROST ON THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PIN42 COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENTTO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    Oct 1, 2009, 00:00

  • PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-I-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS

    Oct 1, 2009, 00:00

  • PIH39 VALIDITY AND RELIABILITY OF QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE FOR TURKISH WOMEN

    Oct 1, 2009, 00:00

  • PMH24 ECONOMIC BENEFITS OF ESCITALOPRAM VERSUS DULOXETINE IN SPAIN

    Oct 1, 2009, 00:00

  • PDB7 HOSPITALIZACIONES POR INSUFICIENCIA CARDN VS. LOS DE SU TRATAMIENTO

    Oct 1, 2009, 00:00

  • PND32 NEW QUALITY OF LIFE (QOL) DATA ON UK PATIENTS WITH REFRACTORY NEUROPATHIC PAIN

    Oct 1, 2009, 00:00

  • PMH46 ESTIMATING THE COSTS OF PSYCHIATRIC HOSPITAL SERVICES IN NIGERIA; A CASE STUDY OF FEDERAL NEUROPSYCHIATRIC HOSPITAL ENUGU, SOUTH EAST NIGERIA

    Oct 1, 2009, 00:00

  • PCV119 COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN57 EVALUATION OF THE COMPLICATION RATE AND COST OF TREATMENT ACCORDING TO THE MASCC INDEX IN PATIENTS WITH FEBRILE NEUTROPENIA

    Oct 1, 2009, 00:00

  • PIH21 COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)

    Oct 1, 2009, 00:00

  • PIN79 SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS

    Oct 1, 2009, 00:00

  • PHP32 THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK

    Oct 1, 2009, 00:00

  • PIN63 COST-UTILITY ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN GERMANY

    Oct 1, 2009, 00:00

  • PIH38 RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND MULTIMORBIDITY AMONG OLDER PERSONS IN GERMANY-RESULTS OF THE PRISCUS-COHORT

    Oct 1, 2009, 00:00

  • PND1 RELATIONSHIP BETWEEN ADHERENCE TO INTERFERONS TO TREAT MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES

    Oct 1, 2009, 00:00

  • PCN30 THE BURDEN OF MULTIPLE MYELOMA- ASSESSMENT ON OCCURRENCE, OUTCOMES AND COST USING A RETROSPECTIVE LONGITUDINAL STUDY BASED ON ADMINISTRATIVE CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PCV45 DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS

    Oct 1, 2009, 00:00

  • PMC74 WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISION-MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS

    Oct 1, 2009, 00:00

  • PIH24 CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY- TIME AND SUPPLIES WITH PRINEO* VS. STANDARD OF CARE FOR BREAST RECONSTRUCTION SURGERY

    Oct 1, 2009, 00:00

  • PIH28 VALIDATION OF THE SF-36 IN PATIENTS WITH ENDOMETRIOSIS

    Oct 1, 2009, 00:00

  • PIN78 DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER-A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME

    Oct 1, 2009, 00:00

  • PR3 FIBROMYALGIA FATIGUE-DEVELOPMENT OF A CONCEPTUAL MODEL BASED ON QUALITATIVE PATIENT INTERVIEWS

    Oct 1, 2009, 00:00

  • PIN82 THE APPLICATION OF HEALTH TECNOLOGY ASSESSMENT ON THE NEW PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE IN ITALY

    Oct 1, 2009, 00:00

  • PRS9 THE IMPACT AND COSTS OF REIMBURSED SMOKING CESSATION USING VARENICLINE IN DENMARK

    Oct 1, 2009, 00:00

  • PMS50 COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PHP61 POSITIVE DRUG LIST IN BULGARIA-5 YEARS LATER

    Oct 1, 2009, 00:00

  • PMS49 COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND

    Oct 1, 2009, 00:00

  • PHP59 TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS

    Oct 1, 2009, 00:00

  • PMC21 REAL AND THEORETICAL COST OF ABSENTEEISM IN POLAND

    Oct 1, 2009, 00:00

  • PR2 IMPROVEMENT IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH ADALIMUMAB PLUS METHOTREXATE- WORK OUTCOMES AND THEIR CORRELATIONS WITH CLINICAL AND RADIOGRAPHIC MEASURES FROM A RANDOMIZED C ...

    Oct 1, 2009, 00:00

  • PMC47 WILLINGNESS TO INITIATE THERAPY AND PUBLIC HEALTH POLICY- AN APPLICATION TO THE STRATEGIC DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR HEPATITIS C TREATMENT

    Oct 1, 2009, 00:00

  • PRS27 MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD IN GERMANY

    Oct 1, 2009, 00:00

  • PND3 BUDGET IMPACT ANALYSIS OF FIXED DOSAGE COMBINATION (FDC) OF LEVODOPA/CARBIDOPA/ENTACAPONE IN PARKINSON DISEASE TREATMENT BY SO PAULO PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PIN44 A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY

    Oct 1, 2009, 00:00

  • ISPOR 2ND LATIN AMERICA CONFERENCE DISCLOSURE INFORMATION

    Oct 1, 2009, 00:00

  • PMC56 PREFERENCES FOR PREFERENCES

    Oct 1, 2009, 00:00

  • PMH34 COSTS OF SCHIZOPHRENIA WITHIN A LARGE GERMAN STATUTORY HEALTH INSURANCE FUND

    Oct 1, 2009, 00:00

  • PHP58 MEDICARE DRUG PAYMENT AND PHARMACY HANDLING COSTS- HOW FAR HAVE WE COME?

    Oct 1, 2009, 00:00

  • PCN1 BURDEN OF THROMBOCYTOPENIA IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY, 2000-2007

    Oct 1, 2009, 00:00

  • PHP10 QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY- A METHODOLOGICAL APPROACH

    Oct 1, 2009, 00:00

  • PSY52 DEFI A FRENCH PREVALENCE STUDY OF FIBROMYALGIA (FM), HEALTH RELATED QUALITY OF LIFE - SF36

    Oct 1, 2009, 00:00

  • PDB49 UNDERSTANDING AND ASSESSING THE IMPACT OF GROWTH HORMONE DEFICIENCY IN ADULTS

    Oct 1, 2009, 00:00

  • PIH6 CHANGES OF HEART RATE VARIABILITY AFTER SHORT-TERM MEDITATION TRAINING IN COLLEGE STUDENT

    Oct 1, 2009, 00:00

  • PCV99 PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY

    Oct 1, 2009, 00:00

  • PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS- WAS THERE A DIFFERENTIAL EFFECT?

    Oct 1, 2009, 00:00

  • PCN166 TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT- EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION

    Oct 1, 2009, 00:00

  • PCV63 COST OF CARDIOVASCULAR DISEASE IN KOREA- INCIDENCE-BASED APPROACH

    Oct 1, 2009, 00:00

  • PDB39 ECONOMIC ANALYSIS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE I DIABETES MELLITUS IN MEXICO

    Oct 1, 2009, 00:00

  • PIN8 EVALUACIS DE COLOMBIA

    Oct 1, 2009, 00:00

  • VA4 HEALTH ECONOMIC EVALUATION OF A NOVEL INTRADERMAL INFLUENZA VACCINE IN TWO EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PCV65 TWO-YEAR CLINICAL AND ECONOMIC IMPACT OF PERIPHERAL ARTERIAL DISEASE ON PATIENTS FROM SPAIN WITH ESTABLISHED CORONARY ARTERY OR CEREBROVASCULAR DISEASE- RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGIS ...

    Oct 1, 2009, 00:00

  • PSY8 TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN- RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES

    Oct 1, 2009, 00:00

  • PCN10 IMPACTO DE LA SUPERVIVENCIA DEL CDICOS DIRECTOS

    Oct 1, 2009, 00:00

  • PCN26 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB + INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO

    Oct 1, 2009, 00:00

  • PIN2 HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE

    Oct 1, 2009, 00:00

  • PCN79 COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE+DOCETAXEL VS GEMCITABINE+DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE

    Oct 1, 2009, 00:00

  • PMS14 MODELING THE PROGRESSION OF RHEUMATOID ARTHRITIS IN ITALY- BUDGET IMPACT ANALYSIS FOR BIOLOGIC AGENTS

    Oct 1, 2009, 00:00

  • PSS11 COST OF TREATMENT FAILURE IN ACUTE INFECTIOUS CONJUNCTIVITIS IN SCOTLAND, SPAIN, THE NETHERLANDS AND POTENTIAL ECONOMIC BENEFIT OF TOPICAL MOXIFLOXACIN 0.5%

    Oct 1, 2009, 00:00

  • CASE2 REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME

    Oct 1, 2009, 00:00

  • PCV95 COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PND33 LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES

    Oct 1, 2009, 00:00

  • PRS2 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VARENICLINE FOR SMOKING CESSATION COMPARED WITH PLACEBO, NICOTINE REPLACEMENT THERAPY OR SUSTAINED-RELEASE BUPROPION

    Oct 1, 2009, 00:00

  • PHP23 PROPUESTA PARA EL ESTABLECIMIENTO DE UN MODELO DE LA EVALUACIA

    Oct 1, 2009, 00:00

  • PSS12 THE ECONOMIC IMPACTS OF ACUTE OTITIS MEDIA IN TAIWAN

    Oct 1, 2009, 00:00

  • PDB45 ASSESSING UTILITIES AND DISUTILITIES FOR TYPE 2 DIABETES TREATMENT-RELATED ATTRIBUTES IN AN ASIAN POPULATION

    Oct 1, 2009, 00:00

  • PDB41 COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIH1 PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS

    Oct 1, 2009, 00:00

  • PIH12 ECONOMIC BURDEN OF POSTMENOPAUSAL OSTEOPOROSIS IN GERMANY- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PCN62 COST ANALYSIS OF HORMONE RECEPTOR POSITIVE, ADVANCED BREAST CANCER TREATMENT WITH ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (BPHS)

    Oct 1, 2009, 00:00

  • PUK14 HOW DO PATIENTS DESCRIBE THEIR SYMPTOMS OF INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)? QUALITATIVE INTERVIEWS WITH PATIENTS TO SUPPORT THE DEVELOPMENT OF A PATIENT-REPORTED SYMPTOM-BASED SCREENER FOR IC/PBS

    Oct 1, 2009, 00:00

  • PCN24 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRI ...

    Oct 1, 2009, 00:00

  • PDB13 ENCUESTA SOBRE LAS PRACTICAS DE UTILIZACION Y TITULACION DE INSULINA EN LATINOAMERICA

    Oct 1, 2009, 00:00

  • PND39 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS ON NATALIZUMAB IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PCN126 LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA- EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL

    Oct 1, 2009, 00:00

  • CS20 RELATIONSHIP BETWEEN ADHERENCE LEVEL TO STATINS AND CLINICAL ISSUES AND HEALTH CARE COSTS IN REAL LIFE CLINICAL SETTING

    Oct 1, 2009, 00:00

  • PR1 A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH

    Oct 1, 2009, 00:00

  • PHP8 SURVEY ON THE MANAGEMENT OF ORAL ANTICOAGULATION THERAPY (OAT) IN ITALY

    Oct 1, 2009, 00:00

  • PIN47 MODELING THE OUTCOMES OF VACCINATION WITH THE 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN SPAIN

    Oct 1, 2009, 00:00

  • PDB67 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC

    Oct 1, 2009, 00:00

  • PG16 EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIN33 POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA- A MARKOV MODELLING APPROACH

    Oct 1, 2009, 00:00

  • ISPOR TWELFTH ANNUAL EUROPEAN CONGRESS DISCLOSURE INFORMATION

    Oct 1, 2009, 00:00

  • PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Oct 1, 2009, 00:00

  • PCV154 THE INFLUENCE OF INSURANCE COMPANIES THE EXAMPLE OF SIMVASTATIN AND PREFERENCE POLICY

    Oct 1, 2009, 00:00

  • PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE- A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCV171 CRITICAL APPRAISAL OF THE JAPANESE GUIDELINE FOR THE MANAGEMENT OF STROKE

    Oct 1, 2009, 00:00

  • PCN17 COST EFFECTIVENESS OF IMIQUIMOD IN SUPERFICIAL BASAL CELL CARCINOMA TREATMENT

    Oct 1, 2009, 00:00

  • PMH66 QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES- COMPARISONS OF INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ORAL AND LONG-ACTING INJECTABLE FORMULATIONS OF OLANZAPINE

    Oct 1, 2009, 00:00

  • PIH30 SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD)- CONCEPTS AND MEASUREMENT

    Oct 1, 2009, 00:00

  • PIN4 IMPACT OF CHRONIC HEPATITIS B IN THE BRAZILIAN HEALTH SYSTEM ACCORDING WITH DATA FROM DATASUS (ADMINISTRATIVE DATABASE) FROM MINISTRY OF HEALTH

    Oct 1, 2009, 00:00

  • PMC31 THE MONDRIAAN PROJECT- THE DUTCH HEALTH CARE LANDSCAPE AS A POPULATION LABORATORY

    Oct 1, 2009, 00:00

  • PG19 COST-EFFECTIVENESS OF INTRAVENOUS IRON IN INFLAMMATORY BOWEL DISEASE PATIENTS INTOLERANT TO ORAL IRON

    Oct 1, 2009, 00:00

  • PMC42 COMPARING MARKOV MODEL AND DES-THE EXAMPLE OF COPD

    Oct 1, 2009, 00:00

  • PHP65 PUBLICATION OF COST-EFFECTIVENESS ANALYSES AND SUBSEQUENT CITATIONS IN THE MEDICAL AND HEALTH ECONOMICS LITERATURE

    Oct 1, 2009, 00:00

  • PCN29 REVISNCIAS (MBE)- IMPACTO FINANCEIRO E BUSCA PELA QUALIDADE

    Oct 1, 2009, 00:00

  • PDB38 COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY

    Oct 1, 2009, 00:00

  • PDB32 COST-EFFECTIVENESS OF NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE (CHD), DIABETES MELLITUS TYPE 2 (DMT2) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY

    Oct 1, 2009, 00:00

  • PND12 COST AND RESOURCE USE RELATED TO NEWLY DIAGNOSED MULTIPLE SCLEROSIS- REAL-WORLD DATA FROM A LARGE US CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PCV172 TREATMENT PATTERNS AMONG PATIENTS WITH HYPERTENSION- RESULTS OF A US SURVEY

    Oct 1, 2009, 00:00

  • PCV134 PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY- A RETROSPECTIVE

    Oct 1, 2009, 00:00

  • PMS97 FACTORS INFLUENCING REIMBURSEMENT AND PRESCRIPTION DECISIONS ON THE RHEUMATOID ARTHRITIS MAKET IN GERMANY, SPAIN, ITALY, FRANCE AND UK

    Oct 1, 2009, 00:00

  • PMC65 QUALITATIVE METHODS IN PRO RESEARCH- DEVELOPMENT OF A METHODS MATRIX

    Oct 1, 2009, 00:00

  • PGI2 CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLO PAULO SCHOOL OF MEDICINE (HC-FMUSP)

    Oct 1, 2009, 00:00

  • PRS39 VALIDATION OF THE SPANISH VERSION OF THE 'COPD AND ASTHMA SLEEP IMPACT SCALE (CASIS)' QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PCV106 PREDICTED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE OPTIMAL LIPID VALUES WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH A STATIN IN SPECIAL PATIENT POPULATIONS WITH MIXED DYSLIPIDEMIA

    Oct 1, 2009, 00:00

  • CS5 GASTOS ELEVADOS COM MEDICAMENTOS DO PROGRAMA DE MEDICAMENTOS EXCEPCIONAIS DO MINISTDE/BRASIL

    Oct 1, 2009, 00:00

  • PIN15 EVALUACI D.C

    Oct 1, 2009, 00:00

  • PIN28 ECONOMIC ANALYSIS ABOUT VALGANCICLOVIR PROPHYLAXIS AGAINST INFECTION FROM CITOMEGALOVIRUS IN PATIENTS WITH RENAL TRANSPLANTATION

    Oct 1, 2009, 00:00

  • PCV18 COST OF ACHIEVING LDL REDUCTION AMONG PATIENTS TREATED WITH EZETIMIBE CO-ADMINISTRATION COMPARED TO STATIN MONOTHERAPY IN THE UK

    Oct 1, 2009, 00:00

  • PIN24 DIFFERENT APPROACHES FOR ESTIMATING INDIRECT COST IN THE ECONOMIC ASSESSMENT OF PNEUMOCOCCAL VACCINES IN GERMANY

    Oct 1, 2009, 00:00

  • PMS74 DEVELOPMENT OF A TOOL TO HELP IN THE EARLY DETECTION OF FIBROMYALGIA (FM) IN GENERAL PRACTICE IN EUROPE

    Oct 1, 2009, 00:00

  • PMH22 BUDGET IMPACT OF THE USE OF RISPERIDONE LONG ACTING INJECTABLE IN THE GERMAN HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PRS43 RELIABILITY AND VALIDITY OF THE SMOKER COMPLAINT SCALE

    Oct 1, 2009, 00:00

  • PSS39 PSORIASIS- AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS

    Oct 1, 2009, 00:00

  • DB4 RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PIN34 ECONOMIC ASSESSMENT OF MASS VACCINATION WITH PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN POLAND

    Oct 1, 2009, 00:00

  • PCV140 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS- A UK PILOT STUDY OF WARFARIN-NAVE ATRIAL FIBRILLATION PATIENTS

    Oct 1, 2009, 00:00

  • PSS1 VERTEPORFIN IN NEOVASCULAR AMD- REAL LIFE CONFIRMS CLINICAL TRIALS RESULTS

    Oct 1, 2009, 00:00

  • PIH18 PHARMACOECONOMIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO- INSURANCE COMPANIES PERSPECTIVE

    Oct 1, 2009, 00:00

  • EE3 IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK

    Oct 1, 2009, 00:00

  • PCV170 A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG HUNGARIAN PATIENTS IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PCN100 COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN

    Oct 1, 2009, 00:00

  • PG118 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON GENERIC HEALTH RELATED QUALITY OF LIFE USING THE EQ-5D INDEX SCORES IN PATIENTS WITH CHRONIC NON-MALIGNANT PAIN AND OPIOID-INDUCED CONSTIPATION

    Oct 1, 2009, 00:00

  • PCN94 ECONOMIC EVALUATION OF DOCETAXEL IN THE CONTEXT OF BREAST CANCER IN PORTUGAL

    Oct 1, 2009, 00:00

  • CS15 ECONOMIC BURDEN ASSOCIATED WITH DOSE-TITRATION AT INITIATION TO MANAGED CARE IN PATIENTS WITH NON-PSYCHOTIC MAJOR DEPRESSIVE DISORDER

    Oct 1, 2009, 00:00

  • PCV101 IS PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE GERMAN HEALTH CARE SYSTEM? A MODEL-BASED ANALYSIS

    Oct 1, 2009, 00:00

  • PDB62 ECONOMIC IMPACT OF COMPLIANCE AND PERSISTENCE TO TREATMENT WITH ANTIDIABETES MEDICATION IN T2DM-A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PHP45 THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES-WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES

    Oct 1, 2009, 00:00

  • PND23 HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY LALIMO-TRIAL)

    Oct 1, 2009, 00:00

  • PMC52 ASSESSING THE (DIS) AGREEMENT OF EQ-5D AND SF-6D ACROSS GROUPS WITH INCREASING SEVERITY OF CHRONIC HEART FAILURE

    Oct 1, 2009, 00:00

  • PRS2 BUDGET IMPACT ANALYSIS OF INTRODUCTION FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) INTO THE BRAZILIAN NATIONAL DRUG FORMULARY

    Oct 1, 2009, 00:00

  • PCN22 COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY

    Oct 1, 2009, 00:00

  • PCN21 NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER

    Oct 1, 2009, 00:00

  • DB2 PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY-COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN

    Oct 1, 2009, 00:00

  • PCV46 PERFLUTREN PROTEIN-TYPE A MICROSPHERES INJECTABLE SUSPENSION, USP DOES NOT INCREASE MORTALITY IN CRITICALLY ILL PATIENTS- RESULTS FROM A RETROSPECTIVE PROPENSITY-MATCHED CASE-CONTROL STUDY

    Oct 1, 2009, 00:00

  • PCV34 QUANTIFICATION METHODS OF ITALIAN PREVALENT POPULATION SUFFERING FROM ATRIAL FIBRILLATION USING PUBLISHED EPIDEMIOLOGICAL DATA

    Oct 1, 2009, 00:00

  • PCV112 COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND

    Oct 1, 2009, 00:00

  • PMH2 EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION- EARLY KNOWLEDGE GAIN-LATE CONSEQUENCES IN ROUTINE CARE?

    Oct 1, 2009, 00:00

  • PCV27 COUNTRY-SPECIFIC DIFFERENCES IN 12-MONTH PATTERNS OF ANTIPLATELET USE IN ACS PATIENTS UNDERGOING PCI IN 2007-08- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)

    Oct 1, 2009, 00:00

  • WP4 DISCRETE CHOICE EXPERIMENT TO DETERMINE WILLINGNESS-TO-PAY FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) TREATMENT

    Oct 1, 2009, 00:00

  • PCV103 COST-EFFECTIVENESS OF EXTENDED VERSUS NON-EXTENDED PROPHYLAXIS WITH ENOXAPARIN IN HIGH-RISK SURGICAL PATIENTS IN AUSTRALIA

    Oct 1, 2009, 00:00

  • EE1 USING IQWIGS EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT-A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG

    Oct 1, 2009, 00:00

  • UT2 PARADIGM LOST- A CONCEPTUAL AND EMPIRICAL OBITUARY CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT

    Oct 1, 2009, 00:00

  • PIN1 GENDER DIFFERENCES IN METABOLIC PROFILE AND CARDIOVASCULAR RISK AMONG BRAZILIAN HIV-INFECTED PATIENTS ON HAART- RAPID II STUDY

    Oct 1, 2009, 00:00

  • PIN60 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

    Oct 1, 2009, 00:00

  • PIH44 VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG PHYSICIANS AFTER THE RELEASE OF WHI REPORT

    Oct 1, 2009, 00:00

  • PIH3 ANGICO, NA PERSPECTIVA DO PAGADOR PRIVADO, NO BRASIL

    Oct 1, 2009, 00:00

  • PSY36 CHANGES IN RATES OF SICKLE CELL DISEASE-RELATED INPATIENT STAYS AND ASSOCIATED RESOURCE USE AMONG AFRICAN AMERICANS IN THE UNITED STATES FOLLOWING APPROVAL OF HYDROXYUREA

    Oct 1, 2009, 00:00

  • PCN157 COST-EFFECTIVENESS OF UGT1A1 GENOTYPING IN IRINOTECAN CANCER THERAPY

    Oct 1, 2009, 00:00

  • PCN109 COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING

    Oct 1, 2009, 00:00

  • PHP27 ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES (INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PMS40 COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY

    Oct 1, 2009, 00:00

  • PND29 PARKINSONS DISEASE DRUG THERAPIES- MEDICATION COMPLIANCE AND PERSISTENCE

    Oct 1, 2009, 00:00

  • PMS13 ESTUDIO FARMACOECONUSICAS EN VENEZUELA.

    Oct 1, 2009, 00:00

  • PCN90 MASS SCREENING FOR COLORECTAL CANCER- ARE ALTERNATIVES TO THE GUAIAC FECAL OCCULT BLOOD TEST COST-EFFECTIVE?

    Oct 1, 2009, 00:00

  • PCN50 HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE

    Oct 1, 2009, 00:00

  • PIH12 ANGIAS LEITURA DE PACIENTES EM CONTEXTO DE USO

    Oct 1, 2009, 00:00

  • PCN36 EVIDENCE-BASED MEDICINE (EBM) AND THE PROFILE OF APPEALS FOLLOWING AUDITING IN CHEMOTHERAPY TREATMENTS

    Oct 1, 2009, 00:00

  • CS9 ESTIMATION OF THE BURDEN OF CARDIOVASCULAR DISEASE ATTRIBUTABLE TO MODIFIABLE RISK FACTORS AND COST-EFFECTIVENESS ANALYSIS OF PREVENTIVE INTERVENTIONS TO REDUCE THIS BURDEN IN ARGENTINA

    Oct 1, 2009, 00:00

  • PIH35 THE APPLICATIONS OF GEOGRAPHIC INFORMATION SYSTEM TO QUALITY OF LIFE STUDIES- USING TAIWAN AS AN EXAMPLE

    Oct 1, 2009, 00:00

  • PIN19 TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN URBAN CHINA

    Oct 1, 2009, 00:00

  • PCV80 LONGITUDINAL COST IMPACT OF ATRIAL FIBRILLATION IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES

    Oct 1, 2009, 00:00

  • PHP99 A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS OF ACUPUNCTURE

    Oct 1, 2009, 00:00

  • PCV9 CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATIONS PERSPECTIVE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PSY2 EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE- ARE THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER PATIENTS?

    Oct 1, 2009, 00:00

  • PCN2 ESTUDIO FASE II PARA EVALUAR LA EFICACIA Y SEGURIDAD DE 4N AL VIRUS DEL PAPILOMA HUMANO (VPH) DE ALTO RIESGO

    Oct 1, 2009, 00:00

  • PIN22 ANNUAL COSTS OF CHRONIC HEPATITIS B DISEASE STATES IN PORTUGAL

    Oct 1, 2009, 00:00

  • PCV76 DIRECT COSTS OF DIAGNOSTIC AND TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN GERMANY

    Oct 1, 2009, 00:00

  • PDB10 DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS

    Oct 1, 2009, 00:00

  • PMC43 A CONCEPTUAL FRAMEWORK TO APPLY DISCRETE-EVENT SIMULATION TO ESTIMATE THE RESOURCES NEEDED TO PERFORM A POPULATION BASED CANCER SCREENING PROGRAM

    Oct 1, 2009, 00:00

  • PCN68 US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER

    Oct 1, 2009, 00:00

  • PR6 PRESENTATION OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION SPECIAL INTEREST GROUP (TCA-SIG)

    Oct 1, 2009, 00:00

  • PCN162 REIMBURSEMENT OF ACTIVE-IMMUNOTHERAPEUTICS (AI)- AN ANALYSIS BASED ON A STUDY OF CURENT REIMBURSEMENT APPROACHES

    Oct 1, 2009, 00:00

  • PUK17 CHRONIC OPIOID THERAPY IN ELDERLY PATIENTS WITH IMPAIRED RENAL FUNCTION OR WITH A HIGH RISK OF KIDNEY FAILURE IN GERMANY

    Oct 1, 2009, 00:00

  • PMC33 CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • MO7 EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C

    Oct 1, 2009, 00:00

  • PCN85 COST-EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN RELAPSED MANTLE CELL LYMPHOMA PATIENTS IN CANADA

    Oct 1, 2009, 00:00

  • PCN12 EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY- REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER

    Oct 1, 2009, 00:00

  • PMH29 DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF DULOXETINE VERSUS OTHER ANTIDEPRESSANTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK

    Oct 1, 2009, 00:00

  • PHP19 WHAT DOES BRANDED PHARMA BRING TO LATIN AMERICA AND OTHER EMERGING MARKETS?

    Oct 1, 2009, 00:00

  • PDB11 COMPARATIVE STUDY OF ANNUAL TREATMENT COST OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN MEXICO

    Oct 1, 2009, 00:00

  • PCV64 SHORT AND LONG-TERM ECONOMIC BURDEN OF ISCHEMIC STROKE/TIA PATIENTS

    Oct 1, 2009, 00:00

  • PMS30 COST ANALYSIS OF BALLOON KYPHOPLASTY VERSUS NON SURGICAL MANAGEMENT FOR OSTEOPOROTIC VERTEBRAL FRACTURES IN GERMANY

    Oct 1, 2009, 00:00

  • PND2 BUDGET IMPACT ANALYSIS OF FIXED DOSAGE COMBINATION (FDC) OF LEVODOPA/CARBIDOPA/ENTACAPONE IN PARKINSON DISEASE TREATMENT BY DISTRITO FEDERAL PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA

    Oct 1, 2009, 00:00

  • CS4 THE COST AND HEALTH CONSEQUENCES OF SUBCUTANEOUS IMMUNOTHERAPY PLUS BECLOMETHASONE DIPROPIONATE IN COLOMBIAN CHILDREN WITH MODERATE AND SEVERE ASTHMA

    Oct 1, 2009, 00:00

  • PSY22 COST OF OBESITY TREATMENT IN POLAND

    Oct 1, 2009, 00:00

  • PIN1 FRENCH OBSERVATIONAL COHORT OF HIV-I INFECTED PATIENTS TREATED WITH ENFUVIRTIDE- LONG-TERM EFFICACY AND SAFETY (ZOOM)

    Oct 1, 2009, 00:00

  • PCN113 PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN

    Oct 1, 2009, 00:00

  • PCN69 COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)-RESULTS FROM SPAIN, FRANCE AND ITALY

    Oct 1, 2009, 00:00

  • PHP71 A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)

    Oct 1, 2009, 00:00

  • PRS12 THE CZECH BURDEN STUDY- BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION

    Oct 1, 2009, 00:00

  • PSY53 PELVIC PAIN IN ENDOMETRIOSIS- EFFECT OF PAINKILLERS OR SPORT TO ALLEVIATE SYMPTOMS

    Oct 1, 2009, 00:00

  • PMH11 DIFFERENCES BETWEEN CHILDREN AND ADOLESCENTS IN TREATMENT RESPONSE TO ATOMOXETINE AND THE CORRELATION BETWEEN QOL AND ADHD CORE SYMPTOMS

    Oct 1, 2009, 00:00

  • PP4 LIVES WORTH LIVING- OLDER SMOKERS STATED PREFERENCES FOR LONGEVITY

    Oct 1, 2009, 00:00

  • PCV73 COST-ANALYSIS OF STROKE PATIENTS WITH THE INTEGRATED WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PSS20 ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS- ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB

    Oct 1, 2009, 00:00

  • PCN146 MIND THE GAP- ASSESSING THE DIFFERENT DATA REQUIREMENTS BETWEEN REGULATORY APPROVAL AND HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2009, 00:00

  • PCV127 EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE

    Oct 1, 2009, 00:00

  • PMS91 ADHERENCE IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATED WITH ORAL BISPHOSPHONATES IN GERMANY- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PMH26 A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE

    Oct 1, 2009, 00:00

  • PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER- A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

    Oct 1, 2009, 00:00

  • PCV82 THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE

    Oct 1, 2009, 00:00

  • PCN10 MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE- EFFICACY IN REAL LIFE

    Oct 1, 2009, 00:00

  • PMH72 BENZODIAZEPINE USE AMONG FREQUENT ATTENDERS TO EMERGENCY DEPARTMENTS- A NATIONWIDE STUDY IN TAIWAN

    Oct 1, 2009, 00:00

  • CS11 COST-EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF MAJOR DEPRESSION IN MEXICO

    Oct 1, 2009, 00:00

  • PDB27 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY- A LONG-TERM HEALTH ECONOMIC ANALYSIS

    Oct 1, 2009, 00:00

  • PSY46 HEALTH-RELATED QUALITY OF LIFE BURDEN AMONG FIBROMYALGIA PATIENTS- RESULTS FROM A CROSS-SECTIONAL STUDY IN FRANCE

    Oct 1, 2009, 00:00

  • PRS47 SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES- THE EXAMPLE OF RSV

    Oct 1, 2009, 00:00

  • PND26 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN

    Oct 1, 2009, 00:00

  • PHP2 DISTORNIA

    Oct 1, 2009, 00:00

  • PHP52 AN EVALUATION OF THE POLICY AND THE PROCEDURES OF SUCCESSFUL PHARMACEUTICAL EXPORTERS AND THE COMPARISON IRANIAN COUNTERPART POLICY

    Oct 1, 2009, 00:00

  • CN1 HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER INTERVENTIONS

    Oct 1, 2009, 00:00

  • DE4 PRESCRIPTION DRUG FORMULARIES AND COVERAGE- DOES A DRUG BY ANY OTHER NAME SMELL AS SWEET?

    Oct 1, 2009, 00:00

  • PCN23 ANTICO COM BEVACIZUMABE NO BRASIL

    Oct 1, 2009, 00:00

  • PRS6 LESS THAN 20% OF COPD PATIENTS PERSIST WITH LONG-ACTING INHALED DRUGS FOR AT LEAST THREE YEARS

    Oct 1, 2009, 00:00

  • PMS99 MANAGEMENT OF KNEE OSTEOARTHRITIS- IMPACT ON PAIN ON A DAILY BASIS

    Oct 1, 2009, 00:00

  • PHP16 PARALLEL TRADE OF PHARMACEUTICALS IN POLAND

    Oct 1, 2009, 00:00

  • PCN36 A QUALIDADE DE VIDA DOS DOENTES ONCOLGICOS

    Oct 1, 2009, 00:00

  • PIH2 ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN- A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS)

    Oct 1, 2009, 00:00

  • PSY40 41A COMPARATIVE STUDY ON HEMOPHILIA TREATMENT AND MEDICATION BY THE PRESENCE OF INHIBITORS IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PMS68 GRAND- THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES

    Oct 1, 2009, 00:00

  • PRS16 COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING SMOKING CESSATION STRATEGIES IN HONG KONG

    Oct 1, 2009, 00:00

  • PG17 MANAGEMENT OF OPIOID INDUCED CONSTIPATION (OIC) IN PAIN PATIENTS- A COST OF ILLNESS STUDY IN BELGIUM AND THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PMS43 ECONOMIC EVALUATION OF GLUCOSAMINE SULPHATE TREATMENT IN KNEE OSTEOARTHRITIS

    Oct 1, 2009, 00:00

  • PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN

    Oct 1, 2009, 00:00

  • PCV25 EVALUATION OF THREE METHODS- OF SCHEDULING APPOINTMENT USING SIMULATION EXPERIMENTS

    Oct 1, 2009, 00:00

  • PMS72 A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HAQ, THE SF-6D AND THE EQ-5D IN INFLAMMATORY ARTHRITIS

    Oct 1, 2009, 00:00

  • PMC69 EXAMINING MASLOWS HIERARCHICAL THEORY OF NEEDS BY USING THE ITEMS OF THE WHOQOL-BREF

    Oct 1, 2009, 00:00

  • PDB5 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS

    Oct 1, 2009, 00:00

  • Construct Validity of the Work Productivity and Activity Impairment Questionnaire across Informal Caregivers of Chronically Ill Older Patients

    Sep 1, 2009, 00:00

  • Costs of Medication Nonadherence in Patients with Diabetes Mellitus- A Systematic Review and Critical Analysis of the Literature

    Sep 1, 2009, 00:00

  • Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events- Results from the CHARISMA Trial

    Sep 1, 2009, 00:00

  • Large Impact of Antidiabetic Drug Treatment and Hospitalizations on Economic Burden of Diabetes Mellitus in The Netherlands during 2000 to 2004

    Sep 1, 2009, 00:00

  • Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer

    Sep 1, 2009, 00:00

  • Enhancing Value of Information Analyses

    Sep 1, 2009, 00:00

  • Psychometric Development and Validation of the Chronic Constipation Treatment Satisfaction Questionnaire (CTSAT-Q)

    Sep 1, 2009, 00:00

  • Effects of Mode and Order of Administration on Generic Health-Related Quality of Life Scores

    Sep 1, 2009, 00:00

  • Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe—The HEALTH Model

    Sep 1, 2009, 00:00

  • The Effect of Identifying Macroprolactinemia on Health-Care Utilization and Costs in Patients with Elevated Serum Prolactin Levels

    Sep 1, 2009, 00:00

  • The Effect of Waiting Time on Health-Related Quality of Life, Pain, and Physical Function in Patients Awaiting Primary Total Hip Replacement- A Randomized Controlled Trial

    Sep 1, 2009, 00:00

  • Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial

    Sep 1, 2009, 00:00

  • Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia

    Sep 1, 2009, 00:00

  • Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedule

    Sep 1, 2009, 00:00

  • Predicting an SF-6D Preference-Based Score Using MCS and PCS Scores from the SF-12 or SF-36

    Sep 1, 2009, 00:00

  • Why Do Patients with Inflammatory Arthritis Often Score States “Worse than Death” on the EQ-5D? An Investigation of the EQ-5D Classification System

    Sep 1, 2009, 00:00

  • A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

    Sep 1, 2009, 00:00

  • Cost-Effectiveness of New-Generation Oral Cholera Vaccines- A Multisite Analysis

    Sep 1, 2009, 00:00

  • No Study Left Behind- A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data

    Sep 1, 2009, 00:00

  • Assessing Utility Where Short Measures Are Required- Development of the Short Assessment of Quality of Life-8 (AQoL-8) Instrument

    Sep 1, 2009, 00:00

  • The Impact of Drug Vintage on Patient Survival- A Patient-Level Analysis Using Quebec's Provincial Health Plan Data

    Sep 1, 2009, 00:00

  • A Conceptual Model of the Experience of Dyspnea and Functional Limitations in Chronic Obstructive Pulmonary Disease

    Sep 1, 2009, 00:00

  • How Do Type 2 Diabetes Mellitus-Related Chronic Complications Impact Direct Medical Cost in Four Major Cities of Urban China?

    Sep 1, 2009, 00:00

  • Challenges of Patient-Reported Outcome Assessment in Hemophilia Care—a State of the Art Review

    Jul 1, 2009, 00:00

  • Can NICE Be Nicer? In a World of Budget Constraints There Are No Easy Solutions

    Jul 1, 2009, 00:00

  • Age-Based Programs for Vaccination against HPV

    Jul 1, 2009, 00:00

  • Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

    Jul 1, 2009, 00:00

  • The Impact of Two Pharmaceutical Risk-Sharing Agreements on Pricing, Promotion, and Net Health Benefits

    Jul 1, 2009, 00:00

  • Item Reduction and Psychometric Validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS)

    Jul 1, 2009, 00:00

  • Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting- A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data

    Jul 1, 2009, 00:00

  • Is There Anything Nicer than NICE? A Question the Conservative Shadow Health Team Is Right to Ask

    Jul 1, 2009, 00:00

  • The Linkage between Pediatric Quality of Life and Health Conditions- Establishing Clinically Meaningful Cutoff Scores for the PedsQL

    Jul 1, 2009, 00:00

  • Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire

    Jul 1, 2009, 00:00

  • Valuing Condition-Specific Health States Using Simulation Contact Lenses

    Jul 1, 2009, 00:00

  • Feasibility, Reliability, and Validity of Three Health-State Valuation Methods Using Multiple-Outcome Vignettes on Moderate-Risk Pregnancy at Term

    Jul 1, 2009, 00:00

  • Health-Care Costs of Pediatric Clients Developing Adverse Events during Treatment with Antipsychotics

    Jul 1, 2009, 00:00

  • The Transferability of Economic Evaluations- Testing the Model of Welte

    Jul 1, 2009, 00:00

  • Comparison of Different Valuation Methods for Population Health Status Measured by the EQ-5D in Three European Countries

    Jul 1, 2009, 00:00

  • Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer

    Jul 1, 2009, 00:00

  • Rasch Measurement Properties of the KIDSCREEN Quality of Life Instrument in Children with Cerebral Palsy and Differential Item Functioning between Children with and without Cerebral Palsy

    Jul 1, 2009, 00:00

  • The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer- An Analysis Based On Updated Results from the HERA Trial

    Jul 1, 2009, 00:00

  • What Is the Best Strategy for Diagnosis and Treatment of Helicobacter pylori in the Prevention of Recurrent Peptic Ulcer Bleeding? A Cost-Effectiveness Analysis

    Jul 1, 2009, 00:00

  • Hypoactive Sexual Desire Disorder in Postmenopausal Women- Quality of Life and Health Burden

    Jul 1, 2009, 00:00

  • Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis

    Jul 1, 2009, 00:00

  • Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States

    Jul 1, 2009, 00:00

  • Obesity and Incremental Hospital Charges among Patients with and without Diabetes in the United States

    Jul 1, 2009, 00:00

  • Characterizing Structural Uncertainty in Decision Analytic Models- A Review and Application of Methods

    Jul 1, 2009, 00:00

  • Resource Utilization and Costs of Schizophrenia Patients Treated with Olanzapine versus Quetiapine in a Medicaid Population

    Jul 1, 2009, 00:00

  • A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients- A Third-Party US Payer Perspective

    Jul 1, 2009, 00:00

  • Management of Childhood Urinary Tract Infections- An Economic Modeling Study

    Jun 1, 2009, 00:00

  • Interchangeability of the EQ-5D and the SF-6D in Long-Lasting Low Back Pain

    Jun 1, 2009, 00:00

  • Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom

    Jun 1, 2009, 00:00

  • Transition Probabilities and Predictors of Adherence in a California Medicaid Population Using Antihypertensive and Lipid-Lowering Medications

    Jun 1, 2009, 00:00

  • Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non–small-Cell Lung Cancer in the United States

    Jun 1, 2009, 00:00

  • Argentine Valuation of the EQ-5D Health States

    Jun 1, 2009, 00:00

  • Economic Evaluations Alongside Equivalence and Noninferiority Trials—Reply to Letter to the Editor by Afschin Gandjour

    Jun 1, 2009, 00:00

  • Multinational Trials—Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data- The ISPOR Patient-Reported Outcomes Translation and Linguistic ...

    Jun 1, 2009, 00:00

  • Calibration of Disease Simulation Model Using an Engineering Approach

    Jun 1, 2009, 00:00

  • Terminology Used in Medication Adherence Research Must Reflect Current Models of Health Care

    Jun 1, 2009, 00:00

  • The Willingness to Pay for Reducing Pain and Pain-Related Disability

    Jun 1, 2009, 00:00

  • Economic Evaluation of Medical Devices and Drugs—Same or Different?

    Jun 1, 2009, 00:00

  • Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures- ISPOR ePRO Good Research Practices Task Force Report

    Jun 1, 2009, 00:00

  • Belgian Methodological Guidelines for Pharmacoeconomic Evaluations- Toward Standardization of Drug Reimbursement Requests

    Jun 1, 2009, 00:00

  • Economic Evaluations Alongside Equivalence and Noninferiority Trials

    Jun 1, 2009, 00:00

  • Impact of Patient Selection Criteria and Treatment History on Comparisons of Alternative Therapies- A Case Study of Atypical Antipsychotics

    Jun 1, 2009, 00:00

  • Model-Based Cost-Effectiveness Analyses for the Treatment of Acute Stroke Events- A Review and Summary of Challenges

    Jun 1, 2009, 00:00

  • Assessing the Clinical and Cost-Effectiveness of Medical Devices and Drugs- Are They That Different?

    Jun 1, 2009, 00:00

  • Confirmatory Factor Analysis and Sample Invariance of the Chinese Patient Satisfaction Questionnaire (ChPSQ-9) among Patients with Breast and Lung Cancer

    Jun 1, 2009, 00:00

  • Health Technology Assessment- A Perspective from Germany

    Jun 1, 2009, 00:00

  • A Comparison of Physician and Patient Time Trade-Offs for Postoperative Hip Outcomes

    Jun 1, 2009, 00:00

  • Valuation and Preliminary Validation of the Greek 15D in a Sample of Patients with Coronary Artery Disease

    Jun 1, 2009, 00:00

  • About the Authors

    Jun 1, 2009, 00:00

  • Lessons for Health Technology Assessment- It Is Not Only about the Evidence

    Jun 1, 2009, 00:00

  • Editorial- Pursuing Efficiency- A Dead End for HTA?

    Jun 1, 2009, 00:00

  • Women's Preferences for Attributes of First-Trimester Miscarriage Management- A Stated Preference Discrete-Choice Experiment

    Jun 1, 2009, 00:00

  • Health Technology Assessment in Canada- 20 Years Strong?

    Jun 1, 2009, 00:00

  • Transferability of Economic Evaluations Across Jurisdictions- ISPOR Good Research Practices Task Force Report

    Jun 1, 2009, 00:00

  • The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients

    Jun 1, 2009, 00:00

  • Health Technology Assessment- Reflections from the Antipodes

    Jun 1, 2009, 00:00

  • An Economic Evaluation of Valsartan for Post-MI Patients in the UK Who Are Not Suitable for Treatment with ACE Inhibitors

    Jun 1, 2009, 00:00

  • Health Technology Assessment in Health-Care Decisions in the United States

    Jun 1, 2009, 00:00

  • The Transferability of Economic Data- A Difficult Endeavor

    Jun 1, 2009, 00:00

  • Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

    Jun 1, 2009, 00:00

  • Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment- 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study

    Jun 1, 2009, 00:00

  • Comparing Methodologies for the Allocation of Overhead and Capital Costs to Hospital Services

    Jun 1, 2009, 00:00

  • Valuing Experience Factors in the Provision of Chlamydia Screening- An Application to Women Attending the Family Planning Clinic

    Jun 1, 2009, 00:00

  • Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder

    Jun 1, 2009, 00:00

  • Economic Data Transferability for HTA- Are We There Yet?

    Jun 1, 2009, 00:00

  • Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale

    Jun 1, 2009, 00:00

  • Whose Quality of Life? Ethical Implications in Patient-Reported Health Outcome Measurement

    Jun 1, 2009, 00:00

  • Health Technology Assessment and Evidence-Based Medicine- What Are We Talking About?

    Jun 1, 2009, 00:00

  • Assessing Items on the SF-8 Japanese Version for Health-Related Quality of Life- A Psychometric Analysis Based on the Nominal Categories Model of Item Response Theory

    Jun 1, 2009, 00:00

  • Health Technology Assessment- Lessons Learned from Around the World—An Overview

    Jun 1, 2009, 00:00

  • Economic Evaluation for Devices and Drugs—Same or Different?

    Jun 1, 2009, 00:00

  • Risk Perception and Preference for Prevention of Alzheimer's Disease

    Jun 1, 2009, 00:00

  • PND21 FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2009, 00:00

  • PCN77 HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH ESCALATING IMATINIB VERSUS SWITCHING TO DASATINIB IN PATIENTS WITH CHRONIC MYELEGENOUS LEUKEMIA

    May 1, 2009, 00:00

  • PIH29 COMPARISON OF ADHERENCE, PERSISTENCE AND MEDICATION WASTAGE IN 30-DAY VERSUS 90-DAY REFILL CHANNELS

    May 1, 2009, 00:00

  • PCN17 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, UK AND ITALY- BEVACIZUMAB (BEV) INTERFERON-ALPHA2A COMPARED WITH SUNITINIB

    May 1, 2009, 00:00

  • PND19 EXPLORATORY ANALYSES AND MODELING FOR RELATIVE COSTS OF INFANTS WITH HYDROCEPHALUS

    May 1, 2009, 00:00

  • PSY6 CONTRIBUTIONS OF THE HUNTER OUTCOME SURVEY (HOS) TO ADVANCING UNDERSTANDING OF HUNTER SYNDROME

    May 1, 2009, 00:00

  • PND26 UTILITIES FOR MODERATE ALZHEIMERS DISEASE- RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA

    May 1, 2009, 00:00

  • PCV23 SEASONAL, WEEKLY AND DAILY VARIATION OF ACUTE MYOCARDIAL INFARCTION AND TRANSIENT ISCHEMIC ATTACK IN HUNGARY

    May 1, 2009, 00:00

  • PUK4 THE EFFECTS OF CALCIUM-BASED VS. NON CALCIUM-BASED PHOSPHATE BINDERS ON OUTCOMES AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE- A META-ANALYSIS

    May 1, 2009, 00:00

  • PMC12 VALIDATION OF HEALTH CARE RESOURCE USE QUESTIONNAIRES IN MEXICO

    May 1, 2009, 00:00

  • PSY51 OBESITY AND MEDICARE EXPENDITURE- ACCOUNTING FOR AGERELATED HEIGHT LOSS

    May 1, 2009, 00:00

  • ND4 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS- MODEL UTILIZING FIVE YEAR BENEFIT DATA

    May 1, 2009, 00:00

  • HT4 IN PROMETHEUS SHADOW- EPIDEMIOLOGICAL AND ETHICAL PERSPECTIVES ON OUTCOMES OF CARDIOPULMONARY RESUSCITATION

    May 1, 2009, 00:00

  • PMC35 USE OF CLASSIFICATION TREES AS AN AID IN UNDERSTANDING MISSING DATA- AN EXAMPLE FROM AN INTERNET-BASED SURVEY OF PATIENT CHARACTERISTICS AND RESOURCE UTILIZATION

    May 1, 2009, 00:00

  • PHP15 ASSESSMENT OF ORPHAN DRUGS DEVELOPED AND DRUG UTILIZATION UNDER THE ORPHAN DRUG ACT- A DESCRIPTIVE EMPIRICAL STUDY

    May 1, 2009, 00:00

  • PIH54 HEALTH CARE UTILIZATION AND COSTS AMONGST WOMEN WITH FEMALE SEXUAL DYSFUNCTION (FSD) AND HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

    May 1, 2009, 00:00

  • PSY46 PATTERNS OF CARE IN THE PHARMACOLOGIC TREATMENT OF MODERATE-TO-SEVERE PSORIASIS

    May 1, 2009, 00:00

  • PCV13 CAN THE RELATIONSHIP BETWEEN AGE AND CHOLESTEROL LEVELS INDICATE EFFECTIVENESS OF LIPID LOWERING THERAPY IN PRIMARY CARE? FRANCE, GERMANY, ITALY AND UK

    May 1, 2009, 00:00

  • PCV59 ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT- RESULTS FROM THE ENDEAVOR II TRIAL

    May 1, 2009, 00:00

  • PMH83 FACTORS THAT INFLUENCE DECISIONS AMONG MBHO NETWORK PHYSICIANS TO USE OFFICE-BASED OPIOID TREATMENT OR TO INCREASE THE NUMBER OF OPIOID-DEPENDENT PATIENTS THEY TREAT- RESULTS FROM THE OBOT ATTITUDE AND INTENTION PHYSICIAN SURVEY

    May 1, 2009, 00:00

  • PND22 COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS

    May 1, 2009, 00:00

  • PCN3 THE FEASIBILITY AND COST OF EARLY DETECTION OF PROSTATE CANCER IN GASTROENTEROLOGY UNITS

    May 1, 2009, 00:00

  • PCV86 FLUSHING ASSESSMENT TOOL (FAST)- PSYCHOMETRIC PROPERTIES OF A NEW MEASURE ASSESSING FLUSHING SYMPTOMS

    May 1, 2009, 00:00

  • PSY36 THE HEALTH BURDEN OF NEUROPATHIC PAIN- A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES

    May 1, 2009, 00:00

  • PMC1 CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE LATENT CLASS ANALYSIS (LCA)

    May 1, 2009, 00:00

  • PHP54 EVALUATING DIFFERENCES IN DRUG REIMBURSEMENT BETWEEN MAIL-ORDER AND COMMUNITY PHARMACY

    May 1, 2009, 00:00

  • PSY26 COST OF OPIOID USE IN A COMMERCIALLY INSURED POPULATION OF FIBROMYALGIA PATIENTS

    May 1, 2009, 00:00

  • PIH20 INCREMENTAL COST OF OTITIS MEDIA AMONG CHILDREN IN THE UNITED STATES

    May 1, 2009, 00:00

  • PMS16 ESTIMATION OF LIFE EXPECTANCIES AND LOSS OF LIFE EXPECTANCIES FOR WORKERS WITH PERMANENT OCCUPATIONAL DISABILITY OF UPPER AND LOWER LIMBS- A FOLLOW-UP STUDY OF 69,964 WORKERS FOR 21 YEARS

    May 1, 2009, 00:00

  • PCN85 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EORTC QLQ-C30

    May 1, 2009, 00:00

  • PUK5 COMPARISON OF LIFE EXPECTANCY, EXPECTED YEARS OF LIFE LOST AND SURVIVAL BETWEEN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS

    May 1, 2009, 00:00

  • PMS8 BIOLOGIC THERAPY REDUCES PATIENT-REPORTED SEVERITY OF RHEUMATOID ARTHRITIS IN THE REAL WORLD SETTING

    May 1, 2009, 00:00

  • PHP60 OVERVIEW OF POST-MARKETING DRUG SAFETY SURVEILLANCE IN SOME DEVELOPING COUNTRIES AND WELL DEVELOPED REGIONS

    May 1, 2009, 00:00

  • PIH56 CARESS- THE CANADIAN REGISTRY OF SYNAGIS, SUMMARY OF 2006-2008 RSV SEASONS

    May 1, 2009, 00:00

  • HT1 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT (HTA)

    May 1, 2009, 00:00

  • PMH56 MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE ER AFTER SUBOPTIMAL RESPONSE TO ORAL RISPERIDONE

    May 1, 2009, 00:00

  • PCN55 ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH BREAST CANCER

    May 1, 2009, 00:00

  • PCN100 EVALUATING THE EFFECTIVENESS OF PRIMARY PROPHYLACTIC G-CSF UTILIZED AS AN ADJUNCT TO CHEMOTHERAPY IN BREAST CANCER PATIENTS

    May 1, 2009, 00:00

  • PIH48 RELATIONSHIP BETWEEN DRUG COST COVERAGE AND PRESCRIPTION DECISION MAKING IN MEDICARE PART D ENROLLEES

    May 1, 2009, 00:00

  • PIH47 POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY USING JAPANESE BEERS CRITERIA

    May 1, 2009, 00:00

  • PHC3 COST-EFFECTIVENESS ANALYSIS OF PIMOBENDAN COMPARED TO BENAZEPRIL FOR THE TREATMENT OF ACQUIRED MYXOMATOUS MITRAL VALVE DISEASE IN DOGS IN GERMANY

    May 1, 2009, 00:00

  • PCN72 COST-UTILITY ANALYSIS OF GEFITINIB VERSUS DOCETAXEL IN A MEXICAN PUBLIC INSTITUTION

    May 1, 2009, 00:00

  • PCN25 DRUG UTILIZATION AND COSTS FOR ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN PATIENTS WITH BREAST, LUNG, OR GASTROINTESTINAL CANCER RECEIVING CHEMOTHERAPY

    May 1, 2009, 00:00

  • PMH46 PREDICTORS OF DULOXETINE TREATMENT PERSISTENCE FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2009, 00:00

  • PRS13 THE IMPACT OF ASTHMA ON LOSS OF PRODUCTIVITY AND MEDICAL COSTS

    May 1, 2009, 00:00

  • PMH57 JOB SATISFACTION AMONG HOSPITAL PHARMACISTS IN TAIWAN

    May 1, 2009, 00:00

  • PDB55 UTILIZATION OF ANTIDIABETIC MEDICATIONS OF PATIENTS WITH TYPE 2 DIABETES COVERED BY VARIOUS TYPES OF HEALTH INSURANCE IN A US NATIONAL REPRESENTATIVE POPULATION IN YEAR 2005-2006

    May 1, 2009, 00:00

  • PCV32 HEALTH ECONOMICS EVALUATION ON PERCUTANEOUS CORONARY INTERVENTION(PCI) IN CHINA

    May 1, 2009, 00:00

  • PIN57 FACTORS AFFECTING CHOICE OF ANTIBIOTIC USE IN ACUTE BACTERIAL RESPIRATORY TRACT INFECTIONS- A SURVEY IN THAI PHYSICIANS

    May 1, 2009, 00:00

  • RR2 HEALTH CARE UTILIZATION AND COST OF COPD IN A MEDICAID POPULATION- THE ROLE OF CO-MORBID CONDITIONS

    May 1, 2009, 00:00

  • PCV102 INFLUENCE OF COPAYMENT DIFFERENTIAL BETWEEN GENERIC AND PREFERRED BRAND PRESCRIPTIONS DRUGS ON GENERIC FILL RATE

    May 1, 2009, 00:00

  • PND24 BURDEN OF MULTIPLE SCLEROSIS ON HEALTH-RELATED QUALITY OF LIFE- BASELINE FINDINGS FROM AN OBSERVATIONAL STUDY

    May 1, 2009, 00:00

  • PHP65 THE IMPACT AND CHALLENGES OF INCLUDING PATIENT COST SHARING IN COST-EFFECTIVENESS ANALYSES FROM THE PAYER PERSPECTIVE

    May 1, 2009, 00:00

  • MO4 RE-EXAMINING THE SPECIFICATION OF REGRESSION MODELS OF MULTINOMIAL RESPONSES- AN APPLICATION TO PREDICTING POSTSTROKE DISCHARGE DISPOSITION

    May 1, 2009, 00:00

  • PSS8 COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND SKINSTRUCTURE INFECTIONS TREATMENT IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO

    May 1, 2009, 00:00

  • PHP95 MEDICATION ADMINISTRATION PROCESS CONDUCTED BY NURSES IN INTENSIVE AND ACUTE CARE UNITS OF A HOSPITAL- A TIME AND MOTION STUDY

    May 1, 2009, 00:00

  • PND12 COST-EFFECTIVENESS OF RASAGILINE VERSUS ROPINIROLE EXTENDED RELEASE IN DELAYING LEVODOPA IN THE TREATMENT OF EARLY PARKINSONS DISEASE IN THE UNITED STATES

    May 1, 2009, 00:00

  • PUK16 THE BRAZILIAN PORTUGUESE VALIDATION OF THE URINARY INCONTINENCE-SPECIFIC QUALITY OF LIFE INSTRUMENT- I-QOL

    May 1, 2009, 00:00

  • PRS30 MEDICATION NON-FULFILLMENT AND NON-PERSISTENCE AMONG 29,000 ADULTS WITH CHRONIC DISEASE- HOW OFTEN AND WHY

    May 1, 2009, 00:00

  • PMC22 DIFFERENCE-IN-DIFFERENCE ANALYSIS IN THE EVALUATION OF AN INPATIENT INTERVENTION AMONG PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

    May 1, 2009, 00:00

  • PIN50 DRUG UTILIZATION REVIEW OF ANTIMICROBIAL DRUGS IN AN OUTPATIENT PRIVATE PEDIATRIC SETTING

    May 1, 2009, 00:00

  • PSY44 USE OF POLYPHARMACY IN PATIENTS WITH FIBROMYALGIA

    May 1, 2009, 00:00

  • PHP4 CHANGES OF THE CASE-MIX INDEX OF THE HUNGARIAN INTENSIVE CARE UNITS

    May 1, 2009, 00:00

  • MO3 INTEGRATING INDIVIDUAL PATIENT LEVEL RCT DATA WITH A COMPREHENSIVE DECISION ANALYTIC COST EFFECTIVENESS MODEL

    May 1, 2009, 00:00

  • PDB27 DIRECT COST OF DIABETES IN OPD CLINICS OF PAKISTAN

    May 1, 2009, 00:00

  • PDB53 SHORT-TERM OUTCOMES FOR AN EMPLOYER SPONSERED PHARMACIST- PROVIDED MULTI CENTER DIABETES MANAGEMENT PROGRAM

    May 1, 2009, 00:00

  • PDB21 ECONOMIC EVALUATION OF RAPID-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS IN CANADA

    May 1, 2009, 00:00

  • PMC8 SYSTEMATIC REVIEW RELIABILITY- EFFICACY OF TWO INDEPENDENT REVIEWERS AND TWO-STEP REVIEWS

    May 1, 2009, 00:00

  • PHP68 DISCHARGE AGAINST MEDICAL ADVICE (DAMA)- THE CASE OF PAYER STATUS

    May 1, 2009, 00:00

  • PMH1 ALPRAZOLAM-RELATED DEATHS IN WEST VIRGINIA

    May 1, 2009, 00:00
  • «
  • 141
  • 142
  • 143
  • 144 (current)
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • »